In the BioHarmony Drug Report Database
Lixisenatide
Adlyxin, Lyxumia (lixisenatide) is a protein pharmaceutical. Lixisenatide was first approved as Adlyxin on 2013-01-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Trade Name
|
Lyxumia |
|---|---|
Common Name
|
lixisenatide |
ChEMBL ID
|
CHEMBL2108336 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Peptides |
Image (chem structure or protein)
